Trial reportBritish journal of clinical pharmacology2011
Pharmacokinetics of combined treatment with praziquantel and albendazole in neurocysticercosis.
Trial report in British journal of clinical pharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00441285 (Antiparasitic Therapy for Neurocysticercosis), which is not on this map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Antiparasitic Therapy for Neurocysticercosis: Phase II/III Study on Safety and Efficacy of Combined Treatment With Praziquantel and Albendazole
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- Lack of Clinical Pharmacokinetic Studies to Optimize the Treatment of Neglected Tropical Diseases: A Systematic Review.Clinical pharmacokinetics · 2017Pooled it
- Cysticidal Efficacy of Combined Treatment With Praziquantel and Albendazole for Parenchymal Brain Cysticercosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016Trial
- Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial.The Lancet. Infectious diseases · 2014Trial
- Postoperative Prophylaxis of Cystic Echinococcosis with Albendazole and Praziquantel: A Retrospective Cohort Study.Biomedicines · 2026Article
- Taenia solium neurocysticercosis: Its current epidemiological, diagnostic, therapeutic, and control landscapes.PLoS neglected tropical diseases · 2026Review
- Disseminated Human Subarachnoid Coenurosis.Tropical medicine and infectious disease · 2022Article
- Quality of life in patients with symptomatic epilepsy due to neurocysticercosis.Epilepsy & behavior : E&B · 2022Article
- Update on the diagnosis and management of neurocysticercosis.Arquivos de neuro-psiquiatria · 2022Review
- Neurocysticercosis: A Review into Treatment Options, Indications, and Their Efficacy.Research and reports in tropical medicine · 2022Review
- Frequency and Determinant Factors for Calcification in Neurocysticercosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Parasitic Infections of the Nervous System.Continuum (Minneapolis, Minn.) · 2021Review
- Mortality in Parenchymal and Subarachnoid Neurocysticercosis.The American journal of tropical medicine and hygiene · 2021Article
- Systemic and Target-Site Pharmacokinetics of Antiparasitic Agents.Clinical pharmacokinetics · 2020Review
- Albendazole Sulfoxide Plasma Levels and Efficacy of Antiparasitic Treatment in Patients With Parenchymal Neurocysticercosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Article
- Effect of nitazoxanide on albendazole pharmacokinetics in cerebrospinal fluid and plasma in rats.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2017Article
- Neurocysticercosis: a review on status in India, management, and current therapeutic interventions.Parasitology research · 2017Review
- Update on the Diagnosis and Management of Neurocysticercosis.Current infectious disease reports · 2016Review
- Albendazole and Corticosteroids for the Treatment of Solitary Cysticercus Granuloma: A Network Meta-analysis.PLoS neglected tropical diseases · 2016Article
- Dual Drug Delivery Using Lactic Acid Conjugated SLN for Effective Management of Neurocysticercosis.Pharmaceutical research · 2015Article
- Novel rat model for neurocysticercosis using Taenia solium.The American journal of pathology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 7 institutions in 4 countries.
Funding
Abstract
aimsNeurocysticercosis is the most common cause of acquired epilepsy in the world. Antiparasitic treatment of viable brain cysts is of clinical benefit, but current antiparasitic regimes provide incomplete parasiticidal efficacy. Combined use of two antiparasitic drugs may improve clearance of brain parasites. Albendazole (ABZ) has been used together with praziquantel (PZQ) before for geohelminths, echinococcosis and cysticercosis, but their combined use is not yet formally recommended and only scarce, discrepant data exist on their pharmacokinetics when given together. We assessed the pharmacokinetics of their combined use for the treatment of neurocysticercosis.
methodsA randomized, double-blind, placebo-controlled phase II evaluation of the pharmacokinetics of ABZ and PZQ in 32 patients with neurocysticercosis was carried out. Patients received their usual concomitant medications including an antiepileptic drug, dexamethasone, and ranitidine. Randomization was stratified by antiepileptic drug (phenytoin or carbamazepine). Subjects had sequential blood samples taken after the first dose of antiparasitic drugs and again after 9 days of treatment, and were followed for 3 months after dosing.
resultsTwenty-one men and 11 women, aged 16 to 55 (mean age 28) years were included. Albendazole sulfoxide concentrations were increased in the combination group compared with the ABZ alone group, both in patients taking phenytoin and patients taking carbamazepine. PZQ concentrations were also increased by the end of therapy. There were no significant side effects in this study group.
conclusionsCombined ABZ + PZQ is associated with increased albendazole sulfoxide plasma concentrations. These increased concentrations could independently contribute to increased cysticidal efficacy by themselves or in addition to a possible synergistic effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.